VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
LQDALiquidia Corporation
$75.49$6.7B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLQDAP/E History

LQDA logoLiquidia Corporation (LQDA) P/E Ratio History

Deep Value

Trading at -94.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2026–2026

Current P/E (TTM)
-94.4x
-135% vs 5Y avg
5Y Avg P/E
271.3x
Median 271.3x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$0.22
Price$75.49
Earnings YieldN/A
EPS Growth (1Y)51.8%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 23, 2026, Liquidia Corporation (LQDA) trades at a price-to-earnings ratio of -94.4x, with a stock price of $75.49 and trailing twelve-month earnings per share of $0.22.

The current P/E is 135% below its 5-year average of 271.3x. Over the past five years, LQDA's P/E has ranged from a low of 271.3x to a high of 271.3x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, LQDA trades at a 527% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.

Relative to the broader market, LQDA trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LQDA DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

LQDA Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-94.4vs22.1
-527%
Below Sector
vs. S&P 500
-94.4vs24.3
-488%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 52% EPS growth (1Y)

LQDA P/E vs Peers

Commercial Specialty Pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
UTHR logoUTHRUnited Therapeutics Corporation
$23B19.31.00+13%
MNKD logoMNKDMannKind Corporation
$1B194.5--79%
INVA logoINVAInnoviva, Inc.
$2B6.9Lowest0.66Best+817%Best
PBYI logoPBYIPuma Biotechnology, Inc.
$390M12.6--2%
JNJ logoJNJJohnson & Johnson
$557B39.9--58%
MRK logoMRKMerck & Co., Inc.
$285B15.90.74+8%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

LQDA Historical P/E Data (2026–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$37.74$0.14271.3x+0%

Average P/E for displayed period: 271.3x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LQDA — Frequently Asked Questions

Quick answers to the most common questions about buying LQDA stock.

What is LQDA's P/E ratio?

Liquidia Corporation (LQDA) trailing twelve-month P/E ratio is -94.4x, based on TTM diluted EPS of $0.22. The 5-year average P/E is 271.3x and the historical range spans 271.3x to 271.3x.

Is LQDA stock overvalued or undervalued?

LQDA trades at -94.4x P/E, below its 5-year average of 271.3x. At the 0th percentile of its historical range (271.3x–271.3x), the stock is priced at a discount to its own history.

Is LQDA stock expensive?

No, LQDA is not expensive on a historical basis. The current P/E of -94.4x is below the 5-year average of 271.3x and sits at the 0th percentile of its valuation range.

What is LQDA's historical P/E range?

Over the past 5 years, LQDA's P/E ratio has ranged from 271.3x to 271.3x, with a median of 271.3x and an average of 271.3x. The current P/E of -94.4x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.

How does LQDA's P/E compare to the S&P 500?

LQDA trades at -94.4x P/E versus the S&P 500 median of 24.3x. The 488% discount to the market suggests lower growth expectations or perceived higher risk.

How does LQDA's valuation compare to Healthcare peers?

Liquidia Corporation P/E of -94.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is LQDA's PEG ratio?

LQDA PEG ratio is N/A, based on a P/E of -94.4x and EPS growth of 51.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is LQDA's earnings yield?

LQDA earnings yield is N/A, the inverse of its -94.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

LQDA P/E Ratio History (2026–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current271.3x
Period Avg271.3x
Range271.3x - 271.3x
Change+0%
1 quartersMar 31, 2026 - Mar 31, 2026